{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'medium dose ICS, in combination with a second controller or high-dose ICS alone or in', 'combination with a second controller. This study is designed to investigate the efficacy and safety', 'profile of dupilumab over one year in a population of asthmatic children in need for an additional', 'treatment to their current maintenance management. The presence of a placebo arm is appropriate', 'for the objectives of this study since it will provide the most robust assessment of the efficacy and', 'safety of dupilumab.', 'The proposed study design provides the opportunity to understand better the efficacy of', 'dupilumab on multiple asthma domains including prevention of severe exacerbations, lung', 'function and symptom control. The short and long term effects on lung function and symptom', 'control will be evaluated.', '4.2', 'RATIONALE FOR DOSE SELECTION', 'The dose regimens for pediatric patients aged 6 to <12 years are selected based on the observed', 'efficacy and safety in the dose ranging study in adult asthma patients (Phase 2b study DRI12544),', 'the PK characterization and safety observation in pediatric atopic dermatitis (AD) study', '(R668-AD-1412) of 6 to <18 years, as well as the available blinded safety data of EFC13579, the', 'asthma pivotal study being conducted in adults and adolescents.', 'In the completed Phase 2b dose ranging study (DRI12544), dupilumab efficacy at 4 dose', 'regimens (300 mg once every 4 weeks (q4w) and once every 2 weeks (q2w), and 200 mg q2w and', 'q4w with a total dose on Day 1 of 600 mg for (the 300 mg regimen) and 400 mg (for the 200 mg', 'regimen) respectively, was evaluated in patients with uncontrolled asthma while receiving a stable', 'dose of medium to high-dose ICS/ Long-acting \u00df2 agonist (LABA) in addition to their study', 'treatment (placebo or dupilumab). Dupilumab demonstrated dose dependent improvement,', 'compared with placebo, in the change from baseline in forced expiratory volume in 1 second', '(FEV1) at Week 12. In addition, consistent efficacy results in favor of dupilumab over placebo', 'were observed in the majority of main secondary efficacy endpoints including annualized rate of', 'severe exacerbation events. The maximum treatment effects were observed in the 200 mg and', '300 mg q2w regimens. Exposure-response analyses further supported the maximal effect for both', 'endpoints of FEV1 and severe exacerbation rate approached/achieved at the steady-state exposure', 'of the two q2w regimens (mean steady-state trough concentrations of 28.3 and 58.5 mg/L,', 'respectively). Dupilumab was observed to be safe and well tolerated across all dose regimens', 'examined. Treatment-emergent adverse events (TEAEs) were reported in 79.1% patients in the', 'dupilumab groups (75.3% to 82.8%) and 74.7% patients in the placebo group. The most', 'frequently reported TEAEs included injection site reactions, respiratory tract infections and', 'related symptoms, headache, and back pain. There was no apparent dose relationship for any', 'particular TEAE except for injection site reactions, majority of which were mild in nature.', 'From the available blinded safety data of EFC13579, injection site erythema, nasopharyngitis, and', 'upper respiratory tract infection were the 3 most commonly reported TEAEs among adolescents', 'in this study. None of the TEAEs observed in the 26 adolescents dosed at the time of blinded', 'analysis were severe or serious. No new safety signal was identified in these adolescent patients', 'compared to adults. The top 3 most common TEAEs in adolescents were also the most common', 'reported TEAEs in adults in this study and the DRI12544 study.', 'Property of the Sanofi Group - strictly confidential', 'Page 38', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Study R668-AD-1412 was a Phase 2a, multicenter, open-label, ascending-dose, sequential-cohor', 'study investigating the safety, tolerability, PK, immunogenicity, and efficacy of single-dose and', 'repeat-doses of dupilumab administered subcutaneously (SC) in pediatric patients with moderate', 'to severe AD (for adolescents 12 to <18 years old) or severe AD (for school-going children >6 to', '<12 years old) that was not adequately controlled with topical treatments. The 2 assessed dose', 'regimens at 2 mg/kg and 4 mg/kg corresponds to the weight normalized dose in adults at 150 mg', 'and 300 mg, respectively. Dupilumab administered as single and repeated weekly doses of', '2 mg/kg and 4 mg/kg for 4 weeks was generally safe and well tolerated in both pediatric age', 'groups included in that study. There was a higher incidence of TEAEs following single and', 'repeated weekly administration of 4 mg/kg compared to 2 mg/kg in both age-groups. However,', 'most of the adverse events (AE) were mild in intensity, transient in nature and not related to study', 'drug. There were no new safety signals detected with dupilumab in the pediatric age', '6 to <18 years. The most common AEs reported after both single doses and repeated weekly doses', 'were nasopharyngitis and exacerbation of AD.', 'In study R668-AD-1412, dupilumab administered as a single dose of either 2 mg/kg or 4 mg/kg,', 'in the Study R668-AD-1412, induced significant and rapid reduction of disease activity in patients', 'at Week 2 (34% and 51% reduction in eczema area and severity index (EASI) score from baseline', 'for 2 mg/kg and 4 mg/kg doses respectively. Repeated weekly doses of dupilumab led to a further', 'improvement in disease severity in patients in both dose groups (67% and 70% reduction in', 'EASI score from baseline for 2 mg/kg and 4 mg/kg doses, respectively, at Week 12). There did', 'not appear to be a clear dose response, as the 2 dose groups showed similar efficacy on the', 'various endpoints evaluated during the study.', 'The collective clinical data on the exposure versus efficacy and safety in the adults and pediatric', 'population as observed to date supports a similar exposure-response relationship for efficacy and', 'safety between the adult and pediatric populations down to 6 years of age and justify the approach', 'of selecting EFC14153 dose regimen based on the criteria of matching adult efficacious and safe', 'exposure.', 'Dupilumab PK is not affected by disease status/population in adults. Similar PK profile was', 'observed between healthy subjects, and patients with AD or asthma. Thus, the same PK profile is', 'anticipated in children with asthma and AD which supports the use of AD-1412 PK data for the', 'pediatric asthma dose selection. The observed pediatric PK profile analysis showed general', 'similarity in dupilumab PK profile between adults and children after accounting for body size', 'difference. Similar to adults, body weight (bw) was the only statistically significant covariate of', 'dupilumab PK identified in the pediatric population of 6 to 17 years, where clearance and volume', 'of distribution decreases with decreasing bw following an allometric relationship. There was no', 'significant impact of age and gender on dupilumab PK after adjustment of the bw effect.', 'A pediatric Pop PK model was developed using pediatric data alone (AD-1412) together with', 'single IV dose PK data in healthy volunteers (AS-0907) to further evaluate the typical', 'pharmacokinetics in the pediatric population, and to identify and quantify PK variability', 'component in the pediatric population. The pediatric Pop PK model shares the same two-', 'compartment model structure as that of adults with the first-order absorption, and parallel linear', 'and nonlinear elimination (target-mediated disposition with quasi steady-state QSS', 'approximation).', 'Property of the Sanofi Group - strictly confidential', 'Page 39', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}